Revenue Growth: Arcturus Therapeutics displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 380.67%.

Decline in Revenue: Over the 3 months period, Arcturus Therapeutics faced challenges, resulting in a decline of approximately -10.51% in revenue growth as of 30 September, 2024.

Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF.

Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics.

Analysts have recently evaluated Arcturus Therapeutics and provided 12-month price targets. The average target is $61.43, accompanied by a high estimate of $68.00 and a low estimate of $50.00.

Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $45.00. The company has a 50 day moving average of $12.04 and a two-hundred day moving average of $15.61.

Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT) Q1 2024 Results Conference Call May 8, 2024 4:30 PM ET Company Participants Neda Safarzadeh - Vice President, Head of Investor Relations, Public ...

Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics.

SAN DIEGO, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Arcturus Therapeutics, Inc., a leading RNA medicines company, announced today that it will host a live R&D webcast focused on the “Advances in ...

Get the latest updates on insider buying and selling for Arcturus Therapeutics (NASDAQ:ARCT) today. Stay informed on insider activities and market impact.